Report cover image

Non-Small Cell Lung Cancer (NSCLC) Global Market Opportunities And Strategies To 2034

Publisher The Business Research Company
Published Nov 28, 2025
Length 121 Pages
SKU # BRC20611000

Description

Non-Small Cell Lung Cancer (NSCLC) Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global non-small cell lung cancer (NSCLC) market as it emerges from the COVID-19 shut down.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description:

Where is the largest and fastest-growing market for non-small cell lung cancer (NSCLC)? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The non-small cell lung cancer (NSCLC) market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider non-small cell lung cancer (NSCLC) market; and compares it with other markets.

The report covers the following chapters
  • Introduction and Market Characteristics: - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by therapy and distribution channel.
  • Key Trends: - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
  • Growth Analysis And Strategic Analysis:- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
  • Global Market Size And Growth: Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional And Country Analysis: - Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
  • Market Segmentation: - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by type, by therapy and distribution channel and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
  • Regional Market Size And Growth: - Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Competitive Landscape: - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
  • Other Major And Innovative Companies:- Details on the company profiles of other major and innovative companies in the market.
  • Competitive Benchmarking: - Briefs on the financials comparison between major players in the market.
  • Competitive Dashboard: - Briefs on competitive dashboard of major players.
  • Key Mergers and Acquisitions: - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
  • Recent Developments:- Information on recent developments in the market covered in the report.
  • Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
  • Conclusions And Recommendations- This section includes recommendations for non-small cell lung cancer (NSCLC) providers in terms of product/service offerings geographic expansion, marketing strategies and target groups
  • Appendix:- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:

1) By Type: Squamous Cell Carcinoma; Large Cell Carcinoma; Adenocarcinoma; Other Types

2) By Therapy: Radiation Therapy; Chemotherapy; Targeted Therapy; Immunotherapy; Other Therapies

3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Other Distribution Channels

Companies Mentioned: Merck & Co., Inc.; AstraZeneca; Bristol-Myers Squibb Company; F. Hoffmann-La Roche AG; Pfizer Inc.

Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time-series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; non-small cell lung cancer (NSCLC) indicators comparison.

Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

121 Pages
1 Executive Summary
1.1 Non-Small Cell Lung Cancer (NSCLC) – Market Attractiveness And Macro Economic Landscape
2 Table Of Contents
3 List Of Tables
4 List Of Figures
5 Report Structure
6 Market Characteristics
6.1 General Market Definition
6.2 Summary
6.3 Non-Small Cell Lung Cancer (NSCLC) Market Definition And Segmentations
6.4 Market Segmentation By Type
6.4.1 Squamous Cell Carcinoma
6.4.2 Large Cell Carcinoma
6.4.3 Adenocarcinoma
6.4.4 Other Types
6.5 Market Segmentation By Therapy
6.5.1 Radiation Therapy
6.5.2 Chemotherapy
6.5.3 Targeted therapy
6.5.4 Immunotherapy
6.5.5 Other Therapies
6.6 Market Segmentation By Distribution Channel
6.6.1 Hospital Pharmacy
6.6.2 Online Pharmacy
6.6.3 Other Distribution Channels
7 Major Market Trends
7.1 Bromodomain Inhibitor Gains Fast Track Designations for Resistant Non-Small Cell Lung Cancer
7.2 Dual-Immune Activation Therapy Shows Promise in Immunotherapy-Resistant NSCLC
7.3 Rapid 24-Hour Tumor Profiling for Precision NSCLC Treatment
7.4 Oral Tyrosine Kinase Inhibitors Accelerate Targeted NSCLC Treatment Advances
7.5 FDA Clears Investigational mRNA-Based Precision Immunotherapy
7.6 Third-Generation EGFR-TKI Gains Approval for Stage III NSCLC Maintenance Therapy
8 Global Non-Small Cell Lung Cancer (NSCLC) Growth Analysis And Strategic Analysis Framework
8.1 Global Non-Small Cell Lung Cancer (NSCLC) PESTEL Analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Environmental
8.1.6 Legal
8.2 Analysis Of End Users (B2B)
8.2.1 Hospitals
8.2.2 Specialty Clinics
8.2.3 Homecare
8.2.4 Research Institutes
8.2.5 Other End Users
8.3 Global Non-Small Cell Lung Cancer (NSCLC) Market Growth Rate Analysis
8.4 Historic Market Growth, 2019 – 2024, Value ($ Million)
8.4.1 Market Drivers 2019 – 2024
8.4.2 Market Restraints 2019– 2024
8.5 Forecast Market Growth, 2024 – 2029, 2034F Value ($ Million)
8.6 Forecast Growth Contributors/Factors
8.6.1 Quantitative Growth Contributors
8.6.2 Drivers
8.6.3 Restraints
8.7 Global Non-Small Cell Lung Cancer (NSCLC) Total Addressable Market (TAM)
9 Global Non-Small Cell Lung Cancer (NSCLC) Market Segmentation
9.1 Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
9.2 Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
9.3 Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
9.4 Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Squamous Cell Carcinoma, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
9.5 Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Large Cell Carcinoma, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
9.6 Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Adenocarcinoma, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
9.7 Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Other Types, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
10 Non-Small Cell Lung Cancer (NSCLC) Market, Regional and Country Analysis
10.1 Global Non-Small Cell Lung Cancer (NSCLC) Market, By Region, Historic and Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
10.2 Global Non-Small Cell Lung Cancer (NSCLC) Market, By Country, Historic and Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11 Asia-Pacific Market
11.1 Summary
11.2 Market Overview
11.2.1 Region Information
11.2.2 Market Information
11.2.3 Background Information
11.2.4 Government Initiatives
11.2.5 Regulations
11.2.6 Regulatory Bodies
11.2.7 Major Associations
11.2.8 Taxes Levied
11.2.9 Corporate Tax Structure
11.2.10 Investments
11.2.11 Major Companies
11.3 Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.4 Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.5 Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.6 Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market: Country Analysis
11.7 China Market
11.8 Summary
11.9 Market Overview
11.9.1 Country Information
11.9.2 Market Information
11.9.3 Background Information
11.9.4 Government Initiatives
11.9.5 Regulations
11.9.6 Regulatory Bodies
11.9.7 Major Associations
11.9.8 Taxes Levied
11.9.9 Corporate Tax Structure
11.9.10 Investments
11.9.11 Major Companies
11.10 China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.11 China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.12 China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.13 India Market
11.14 India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.15 India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.16 India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.17 Japan Market
11.18 Summary
11.19 Market Overview
11.19.1 Country Information
11.19.2 Market Information
11.19.3 Background Information
11.19.4 Government Initiatives
11.19.5 Regulations
11.19.6 Regulatory Bodies
11.19.7 Major Associations
11.19.8 Taxes Levied
11.19.9 Corporate Tax Structure
11.19.10 Investments
11.19.11 Major Companies
11.20 Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.21 Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.22 Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.23 South Korea Market
11.24 Summary
11.25 Market Overview
11.25.1 Country Information
11.25.2 Market Information
11.25.3 Background Information
11.25.4 Government Initiatives
11.25.5 Regulations
11.25.6 Regulatory Bodies
11.25.7 Major Associations
11.25.8 Taxes Levied
11.25.9 Corporate Tax Structure
11.25.10 Investments
11.25.11 Major Companies
11.26 South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.27 South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.28 South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.29 Australia Market
11.30 Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.31 Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.32 Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.33 Indonesia Market
11.34 Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.35 Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.36 Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12 Western Europe Market
12.1 Summary
12.2 Market Overview
12.2.1 Region Information
12.2.2 Market Information
12.2.3 Background Information
12.2.4 Government Initiatives
12.2.5 Regulations
12.2.6 Regulatory Bodies
12.2.7 Major Associations
12.2.8 Taxes Levied
12.2.9 Corporate tax structure
12.2.10 Investments
12.2.11 Major Companies
12.3 Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.4 Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.5 Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.6 Western Europe Non-Small Cell Lung Cancer (NSCLC) Market: Country Analysis
12.7 UK Market
12.8 UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.9 UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.10 UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.11 Germany Market
12.12 Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.13 Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.14 Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.15 France Market
12.16 France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.17 France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.18 France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.19 Italy Market
12.20 Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.21 Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.22 Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.23 Spain Market
12.24 Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.25 Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.26 Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13 Eastern Europe Market
13.1 Summary
13.2 Market Overview
13.2.1 Region Information
13.2.2 Market Information
13.2.3 Background Information
13.2.4 Government Initiatives
13.2.5 Regulations
13.2.6 Regulatory Bodies
13.2.7 Major Associations
13.2.8 Taxes Levied
13.2.9 Corporate Tax Structure
13.2.10 Major companies
13.3 Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.4 Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.5 Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.6 Russia Market
13.7 Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.8 Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.9 Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14 North America Market
14.1 Summary
14.2 Market Overview
14.2.1 Region Information
14.2.2 Market Information
14.2.3 Background Information
14.2.4 Government Initiatives
14.2.5 Regulations
14.2.6 Regulatory Bodies
14.2.7 Major Associations
14.2.8 Taxes Levied
14.2.9 Corporate Tax Structure
14.2.10 Investments
14.2.11 Major Companies
14.3 North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14.4 North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14.5 North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14.6 North America Non-Small Cell Lung Cancer (NSCLC) Market: Country Analysis
14.7 USA Market
14.8 Summary
14.9 Market Overview
14.9.1 Country Information
14.9.2 Market Information
14.9.3 Background Information
14.9.4 Government Initiatives
14.9.5 Regulations
14.9.6 Regulatory Bodies
14.9.7 Major Associations
14.9.8 Taxes Levied
14.9.9 Corporate Tax Structure
14.9.10 Investments
14.9.11 Major Companies
14.10 USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14.11 USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14.12 USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14.13 Canada Market
14.14 Summary
14.15 Market Overview
14.15.1 Country Information
14.15.2 Market Information
14.15.3 Background Information
14.15.4 Government Initiatives
14.15.5 Regulations
14.15.6 Regulatory Bodies
14.15.7 Major Associations
14.15.8 Taxes Levied
14.15.9 Corporate Tax Structure
14.15.10 Investments
14.15.11 Major Companies
14.16 Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14.17 Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14.18 Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15 South America Market
15.1 Summary
15.2 Market Overview
15.2.1 Region Information
15.2.2 Market Information
15.2.3 Background Information
15.2.4 Government Initiatives
15.2.5 Regulations
15.2.6 Regulatory Bodies
15.2.7 Major Associations
15.2.8 Taxes Levied
15.2.9 Corporate Tax Structure
15.2.10 Major Companies
15.3 South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.4 South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.5 South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.6 Brazil Market
15.7 Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.8 Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.9 Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
16 Middle East Market
16.1 Summary
16.2 Market Overview
16.2.1 Region Information
16.2.2 Market Information
16.2.3 Background Information
16.2.4 Government Initiatives
16.2.5 Regulations
16.2.6 Regulatory Bodies
16.2.7 Major Associations
16.2.8 Taxes Levied
16.2.9 Corporate Tax Structure
16.2.10 Major Companies
16.3 Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
16.4 Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
16.5 Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
17 Africa Market
17.1 Summary
17.2 Market Overview
17.2.1 Region Information
17.2.2 Market Information
17.2.3 Background Information
17.2.4 Government Initiatives
17.2.5 Regulations
17.2.6 Regulatory Bodies
17.2.7 Major Associations
17.2.8 Taxes Levied
17.2.9 Corporate Tax Structure
17.2.10 Major Companies
17.3 Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
17.4 Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
17.5 Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
18 Competitive Landscape And Company Profiles
18.1 Company Profiles
18.2 Merck & Co., Inc
18.2.1 Company Overview
18.2.2 Products And Services
18.2.3 Business Strategy
18.2.4 Financial Overview
18.3 AstraZeneca plc
18.3.1 Company Overview
18.3.2 Products And Services
18.3.3 Business Strategy
18.3.4 Financial Overview
18.4 Bristol Myers Squibb Company
18.4.1 Company Overview
18.4.2 Products And Services
18.4.3 Business Strategy
18.4.4 Financial Overview
18.5 F. Hoffman-La Roche Ltd
18.5.1 Company Overview
18.5.2 Products And Services
18.5.3 Business Strategy
18.5.4 Financial Overview
18.6 Pfizer Inc
18.6.1 Company Overview
18.6.2 Products And Services
18.6.3 Business Strategy
18.6.4 Financial Overview
19 Other Major And Innovative Companies
19.1 Eli Lilly and Company
19.1.1 Company Overview
19.1.2 Products And Services
19.2 Regeneron Pharmaceuticals Inc.
19.2.1 Company Overview
19.2.2 Products And Services
19.3 Amgen Inc.
19.3.1 Company Overview
19.3.2 Products And Services
19.4 Novartis AG
19.4.1 Company Overview
19.4.2 Products And Services
19.5 Takeda Pharmaceutical Company Limited
19.5.1 Company Overview
19.5.2 Products And Services
19.6 Janssen Biotech, Inc.
19.6.1 Company Overview
19.6.2 Products And Services
19.7 Rigel Pharmaceuticals, Inc.
19.7.1 Company Overview
19.7.2 Products And Services
19.8 Partner Therapeutics/Merus N.V.
19.8.1 Company Overview
19.8.2 Products And Services
19.9 AbbVie Inc.
19.9.1 Company Overview
19.9.2 Products And Services
19.10 Nuvation Bio
19.10.1 Company Overview
19.10.2 Products And Services
19.11 Iovance Biotherapeutics
19.11.1 Company Overview
19.11.2 Products And Services
19.12 Dizal Pharmaceutical
19.12.1 Company Overview
19.12.2 Products And Services
19.13 Daiichi Sankyo / AZ
19.13.1 Company Overview
19.13.2 Products And Services
19.14 Xcovery Holdings, Inc.
19.14.1 Company Overview
19.14.2 Products And Services
19.15 Boehringer Ingelheim
19.15.1 Company Overview
19.15.2 Products And Services
20 Competitive Benchmarking
21 Competitive Dashboard
22 Key Mergers And Acquisitions
22.1 Bristol Myers Squibb Expands Oncology Reach WITH $4.8b Mirati Therapeutics Acquisition
22.2 Pierre Fabre Acquires Vertical Bio To Advance Novel NSCLC Therapy Pipeline
22.3 Bristol Myers Squibb Expands Precision Oncology With $4.1b Turning Point Therapeutics Acquisition
23 Recent Developments In The Non-small Cell Lung Cancer (NSCLC) Market
23.1 First-In-Class PD-1/VEGF Bispecific Antibody Wins Approval For Frontline Lung Cancer Treatment
23.2 FDA Approves Optune Lua Combination Therapy for Advanced Lung Cancer Patients
24 Opportunities And Strategies
24.1 Global Non-Small Cell Lung Cancer (NSCLC) Market In 2029 – Countries Offering Most New Opportunities
24.2 Global Non-Small Cell Lung Cancer (NSCLC) Market In 2029 – Segments Offering Most New Opportunities
24.3 Global Non-Small Cell Lung Cancer (NSCLC) Market In 2029 – Growth Strategies
24.3.1 Market Trend Based Strategies
24.3.2 Competitor Strategies
25 Non-Small Cell Lung Cancer (NSCLC) Market, Conclusions And Recommendations
25.1 Conclusions
25.2 Recommendations
25.2.1 Product
25.2.2 Place
25.2.3 Price
25.2.4 Promotion
25.2.5 People
26 Appendix
26.1 Geographies Covered
26.2 Market Data Sources
26.3 Research Methodology
26.4 Currencies
26.5 The Business Research Company
26.6 Copyright and Disclaimer

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us